Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2

Conditions

Lymphoma 272Lymphoma, Large B-Cell, Diffuse 259Leukemia, Lymphocytic, Chronic, B-Cell 189Lymphoma, Non-Hodgkin 187Lymphoma, Mantle-Cell 165Lymphoma, Follicular 164Lymphoma, B-Cell, Marginal Zone 115Leukemia 94Burkitt Lymphoma 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Waldenstrom Macroglobulinemia 77Lymphoma, B-Cell 62Recurrence 51Hodgkin Disease 50Lymphoma, Large-Cell, Immunoblastic 44Lymphoma, Large-Cell, Anaplastic 20Leukemia, Myeloid, Acute 20Myelodysplastic Syndromes 18Intraocular Lymphoma 15Hematologic Neoplasms 15Neoplasms 14Dendritic Cell Sarcoma, Interdigitating 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Multiple Myeloma 13Leukemia, Hairy Cell 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Neoplasms, Plasma Cell 10Leukemia, Prolymphocytic 10Lymphoma, T-Cell 9Leukemia, Myelomonocytic, Chronic 9

Interventions

Rituximab 3thymoglobulin 1prednylidene 1dexamethasone acetate 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Etoposide 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Carmustine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Opsoclonus-Myoclonus Syndrome × Rituximab × Clear all
NCT01868269 2025-02-03

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Institut Curie

Phase 3 Completed
102 enrolled
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

NCT00202930 2021-01-22

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

University of Pittsburgh

Phase 2 Terminated
4 enrolled 6 charts
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

NCT00244361 2011-05-10

Effectiveness of Rituximab in Pediatric OMS Patients.

National Pediatric Neuroinflammation Organization, Inc.

Phase 1/2 Completed
25 enrolled

Ataxia, Myoclonus, Ocular Motility Disorders, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡